Search 

Medherant uses its unique transdermal delivery technology, the TEPI Patch®, to deliver drugs more effectively.


TEPI Patch enables continuous drug delivery for 24hr and up to 7 days depending on drug and indication. The patches are very thin and comfortable to wear. They do not leave residues on the skin because there is no cold flow and no solvents are used in their manufacture.


The safety of TEPI Patch has been demonstrated in clinical trials. Medherant is developing its own TEPI Patch product and is also working with pharmaceutical company partners to develop transdermal delivery forms of their drugs.

MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. A unique, lifesaving and often cost-saving solution, there are several multi-billion-dollar markets available in oncology, infectious diseases, auto-immune diseases, poisoning, drug overdose and others. 

MediSieve is actively seeking investment and partnerships to complete pre-clinical validation of its second product, which enables novel AAV therapies.

MediWales is the life science network and representative body for Wales.
An independent, not-for-profit organisation that is owned by its members, MediWales provides advice, support, business opportunities and promotes collaborations for the life science and health technology community in Wales.

MediWales delivers an extensive events programme, including the UK HealthTech conference and the MediWales Innovation Awards and produces a number of publications including UK Lifescience Industry magazine, the Annual Directory and Review, and case study magazine LifeStories. MediWales promotes and supports its members in Wales, across the UK and internationally. 

Mursla (Cambridge, UK) is an emergent techbio startup, leveraging extracellular vesicle biology to deliver nextgen multi-omics liquid biopsy tests. 


Its first product is a blood test to significantly improve the early detection of liver cancer among high risk populations so that more patients can benefit from curative treatments (surgery/transplant).


Its test is first-in-class and is differentiated from first generation liquid biopsy blood tests using circulating free DNA since it is tissue-specific, multi-omics and offers real time snapshot of disease biology.


Mursla is currently running a multi-centre pilot study with four world leading universities across Europe and the support of global diagnostic leader, Roche Diagnostics.


Mursla’s lead product is enabled by years of novel technology development to create breakthrough cancer diagnostic tests using extracellular vesicle (EV) biology, seven patents, several publications, its own R&D lab and one of the best EV know-hows globally.


Its first blood test for liver cancer surveillance will be ready for commercial launch in 2025.


Mursla was selected as UK Life Sciences Innovator 2023 in the Diagnostics and Precision Medicine category.


The company's vision is to transform chronic disease management with EV-based multi-omics liquid biopsies.